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Folate-Targeted Nanoparticles Show Efficacy in the
Treatment of Inflammatory Arthritis
Thommey P. Thomas, Sascha N. Goonewardena, Istvan J. Majoros, Alina Kotlyar,
Zhengyi Cao, Pascale R. Leroueil, and James R. Baker, Jr.
Objective. To investigate the uptake of a poly(ami-
doamine) dendrimer (generation 5 [G5]) nanoparticle
covalently conjugated to polyvalent folic acid (FA) as the
targeting ligand into macrophages, and to investigate
the activity of an FA- and methotrexate (MTX)–
conjugated dendrimer (G5-FA-MTX) as a therapeutic
for the inflammatory disease of arthritis.
Methods. In vitro studies were performed in mac-
rophage cell lines and in isolated mouse macrophages to
check the cellular uptake of fluorescence-tagged G5-FA
nanoparticles, using flow cytometry and confocal mi-
croscopy. In vivo studies were conducted in a rat model
of collagen-induced arthritis to evaluate the therapeutic
potential of G5-FA-MTX.
Results. Folate-targeted dendrimer bound and
internalized in a receptor-specific manner into both
folate receptor –expressing macrophage cell lines and
primary mouse macrophages. The conjugate G5-FA-
MTX acted as a potent antiinflammatory agent and
reduced arthritis-induced parameters of inflammation
such as ankle swelling, paw volume, cartilage damage,
bone resorption, and body weight decrease.
Conclusion. The use of folate-targeted nanopar-
ticles to specifically target MTX into macrophages may
provide an effective clinical approach for antiinflamma-
tory therapy in rheumatoid arthritis.
Folate receptors (FRs) comprise a family of
glycosyl phosphatidylinositol–anchored, high-affinity re-
ceptors for folic acid (FA) and are the products of at
least 4 different genes: FR, FR, FR, and FR (1,2).
Although much research has focused on folate receptor
 (FR) as a target for therapy and imaging in oncology,
several recent studies have used FR as a therapeutic
target on macrophages in inflammatory diseases
(3–5). In rheumatoid arthritis (RA), for example, FR
has been shown to be specifically expressed on activated
macrophages in inflamed joints, thus providing a
target for the delivery of both therapeutics and imaging
agents (6–9). Studies have demonstrated the specific
internalization/accumulation of radionuclide-conjugated
FA in inflamed joints of mice, rats, dogs, horses, and
even humans (3).
The feasibility of using FR to mediate the
specific delivery of molecules is based on several unique
biologic characteristics of the FR. First, expression of
FR is specific to the myelomonocytic/macrophage lin-
eages of hematopoietic cells, while there is negligible
expression of this molecule on other blood cells such as
lymphocytes, granulocytes, or erythrocytes (9,10). Sec-
ond, elevated levels of functional glycosylated FR are
expressed only on activated macrophages involved in
inflammatory responses, but not on quiescent resident
macrophages (5,11). In addition, FR is known to be
preferentially expressed at the apical (luminal) side (e.g.,
the urine side in kidney tubules and the air sac side of
the lungs) of normal tissues; therefore, it is possible that
there will be minimal FR binding of circulating folate-
targeted drugs in normal tissues (12). Finally, although
free FA and methotrexate (MTX) can access normal
cells through the ubiquitously expressed reduced folate
carrier (RFC), uptake through this channel does not
occur when FA or MTX is conjugated to a macromole-
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cule like a nanoparticle. These findings together suggest
that activated macrophages are the only predominant
normal cells that could specifically bind and internalize
folate-targeted nanoparticle drugs from circulation
through FR.
MTX is an “antifolate” drug that competes with
FA for binding to the dihydrofolate reductase enzyme
and blocks the 1-carbon transfer reaction used in the
biosynthesis of nucleotides. This inhibits DNA forma-
tion and results in reduced cell proliferation and induc-
tion of apoptosis. For more than 2 decades MTX has
been employed as a disease-modifying antirheumatic
drug (DMARD) for the treatment of RA, either as a
single agent or in combination with biologics such as
tumor necrosis factor (TNF) inhibitors (13,14). The
mechanisms by which MTX suppresses arthritis are
complex and may extend beyond the inhibition of DNA
synthesis in inflammatory cells. These mechanisms may
include increased release of adenosine, altered produc-
tion of cytokines, formation of reactive oxygen species,
T cell apoptosis, and suppression of B cell responses
(4,15,16). Several studies have suggested that at least
one mechanism for MTX activity in RA is through
antiproliferative effects on activated macrophages fol-
lowing specific uptake into these cells via FR
(4,5,9,10,13,15,17–19). Unfortunately, approximately
one-third of RA patients respond poorly to MTX,
while another one-third develop toxic side effects. Pa-
tients with increased side effects may have polymor-
phisms in proteins such as RFC and 5,10-
methylenetetrahydrofolate reductase involved in the
transport and metabolism of free MTX (20–22). Since
the side effects of MTX are the result of its action on
normal cells, either preventing the uptake of MTX in
normal cells or specifically targeting MTX to inflamma-
tory cells independent of the RFC may prevent these
problems.
Poly(amidoamine) (PAMAM) dendrimers have
been extensively employed as a macromolecular delivery
platform and have several attractive properties for this
purpose (Figure 1). These properties include uniformity,
biocompatibility, defined structure, and the capability to
chemically couple multiple molecular entities to primary
surface amino groups (23–26). Many biologic functions
of molecules coupled to the dendrimer’s surface are
retained with a variety of molecules including hormones
such as FA (27,28), peptides (29), antibodies (30),
chemotherapeutic drugs (28,31), or an apoptosis-sensing
fluorochrome (32). Importantly, prior studies from our
laboratory have shown that dendrimers bearing FA can
target FR-expressing xenograft tumors in mice and
increase the therapeutic index of carried MTX 10-fold
(31). In another study, the antiinflammatory drug
indomethacin encapsulated in a generation 4 (G4)
dendrimer–FA conjugate has been shown to preferen-
tially target inflamed tissues in rats, presumably by
targeting FR in macrophages (33). In the present
study, we investigated using FA-bearing G5 dendrimers
to target macrophages in vitro and deliver MTX as an
antiinflammatory agent in a collagen-induced arthritis
model in rats.
MATERIALS AND METHODS
Materials. G5 PAMAM was synthesized and charac-
terized at the Michigan Nanotechnology Institute for Medicine
and Biological Sciences, the University of Michigan, or Den-
dritech. Methanol (high-performance liquid chromatography
[HPLC] grade), acetic anhydride (99%), triethylamine
(99.5%), DMSO (99.9%), dimethylformamide (99.8%), glyci-
dol, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide HCl
(98%), citric acid (99.5%), sodium azide (99.99%), and D2O
were from Sigma. Fluorescein isothiocyanate (FITC) and
5-TAMRA (5T), succinimidyl ester were purchased from
Invitrogen. The murine macrophage cell lines RAW 264.7 and
J774 were obtained from American Type Culture Collection.
The low–FR expressing MCA-207 mouse sarcoma cell line was
kindly provided by Dr. Kevin McDonough at the University of
Figure 1. Schematic representation of the structures and synthesis of
different generations of poly(amidoamine) dendrimers, starting from
the ethylene diamine (EDA) core, and that of the functionalized
dendrimer conjugate G5-FA-MTX. The details of the synthesis steps
and characterization of the conjugate have been previously described
(24,28). Briefly, Michael addition of methylacrylate to EDA followed
by condensation reaction (amidation) yields the generation 0 (G0).
These reaction steps are then repeated to obtain the higher genera-
tions as shown. The G5 is partially (60–70%) acetylated (Ac), the folic
acid (FA) is incorporated through amide linkage, followed by glyci-
dolation (to fully neutralize the surface), and finally the methotrexate
(MTX) is conjugated through ester linkage.
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Kentucky, Louisville. The RPMI 1640 cell culture medium,
trypsin-EDTA, penicillin/streptomycin, Dulbecco’s phosphate
buffered saline (PBS; pH 7.4), Hanks’ balanced salt solution
(HBSS), and fetal bovine serum (FBS) were from Gibco BRL.
Brewer Thioglycollate Medium was prepared by suspending
4.05 grams of Brewer Thioglycollate Medium Powder (Sigma)
in 100 ml deionized water, boiling to dissolve the medium
completely, and autoclaving at 15 lbs/in2 pressure (at 121°C)
for 15 minutes.
Synthesis and characterization of the dendrimer con-
jugates. The intermediates of the synthesis were extensively
purified by dialysis and/or ultrafiltration before proceeding to
the subsequent synthetic step. The final products and all
intermediates have been characterized using 1H nuclear mag-
netic resonance (1H-NMR), matrix-assisted laser desorption
ionization–time-of-flight mass spectrometry, HPLC, gel-
permeation chromatography, and ultraviolet spectroscopy, as
we have described previously (28,32,34). A summary of the
synthetic procedures used is given below, and the physical
properties of the different conjugates are given in Table 1.
FITC conjugates. The FITC conjugates G5-
acetyl(Ac)(74)-FITC(5)-Gly(31) (G5-FITC) and G5-Ac(74)-
FITC(5)-FA(4)-Gly(26) (G5-FITC-FA-1) were synthesized
and characterized using methods previously described (the
numbers of each ligand present per conjugate molecule are
given in parentheses) (28). G5-FITC(3)-FA(4)-Gly(103) (G5-
FITC-FA-2) was synthesized as described (35). The molecular
weight of the material was determined by gel-permeation
chromatography, and the number of ligands (FA/FITC) on
average attached to the dendrimer surface was calculated using
this value in combination with 1H-NMR, accompanied by
potentiometric titration of the starting G5-NH2 dendrimer
(Table 1).
MTX conjugates. Two large-scale batches of G5-Ac-
FA-Gly-MTX (G5-FA-MTX-1 and G5-FA-MTX-2) were syn-
thesized and characterized by Cambrex and by the National
Characterization Laboratory, National Cancer Institute, using
protocols similarly described (28) (Figure 1 and Table 1).
5-TAMRA conjugates. The conjugates G5-Ac(65)-
5T(5)-Gly(48) (G5-5T) and G5-Ac(65)-5T(5)-FA(4)-Gly(40)
(G5-5T-FA) were synthesized and characterized using pro-
cedures similar to those described for the synthesis of
6-TAMRA–based conjugates (36) (see Supplementary Data,
available on the Arthritis & Rheumatism Web site at http://
onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131).
Cell culture and in vitro studies. RAW 264.7 cells were
cultured at 37°C in a humidified atmosphere of 5% CO2 and
95% air, in RPMI 1640 medium containing 10% FBS supple-
mented with penicillin (100 units/ml) and streptomycin
(100 g/ml). The 10% FBS resulted in a final FA concentra-
tion equivalent to that present in human serum (20 nM) and
is designated “low FA medium.” The J774 and MCA-207 cell
lines were cultured in Dulbecco’s modified Eagle’s medium
under similar conditions. In order to induce the expression of
FR, the medium was switched to FA-free RPMI 1640 with
10% FBS 5–7 days prior to performing experiments. Cells were
plated in low FA medium in 24-well plates (for flow cytometry)
or in 35-mm dishes with glass-chambered slides (for confocal
microscopy).
Isolation of mouse peritoneal cavity macrophages.
Mouse peritoneal cavity macrophages were isolated using the
procedure described previously (37). Briefly, the mice were
injected intraperitoneally with 2 ml of Brewer Thioglycollate
Medium 6 days prior to cell isolation. The abdominal wall was
exposed, washed with 70% alcohol, and injected with 5 ml of
a solution of HBSS containing 5% FBS and 10 units/ml sodium































G5-FITC 5.6 1.012 – 98 34.4 – – – 4.6
G5-FITC-FA-1 5.9 1.058 – 98 40.5 4.3 – – 5.2
G5-FITC-FA-2 – – – 95 38.3 4.0 – – 3.0
G5-5T 6.0 1.017 – 99 34.1 – – 6.2 –
G5-5T-FA 7.6 1.092 – 99 35.8 4.1 – 5.3 –
G5-FA-MTX-1 5.9 1.125 11.9 99 40.7 2.5 8.0 – –
G5-FA-MTX-2 6.1 1.096 7.4 99 38.2 5.0 10.5 – –
* The analytic data shown were obtained at the Michigan Nanotechnology Institute for Medicine and Biological Sciences (for G5-FITC,
G5-FITC-FA, G5-5T, and G5-5T-FA); at the National Characterization Laboratory, National Cancer Institute (for drug conjugates); and at
Cambrex (the number of ligands for G5-FA-MTX-2). FA  folic acid; MTX  methotrexate; FITC  fluorescein isothiocyanate; G5  generation
5; 5T  5-TAMRA.
† Calculated as the volume-weighted average over a particular range of size populations corresponding to the most prominent peak in the percent
volume distribution obtained in dynamic light scattering.
‡ A measure of the distribution of molecular mass, with a value of 1 for a fully homogeneous population of molecules.
§ An index of the charge on the dendrimer, measured in phosphate buffered saline. The mean  SD zeta potential of the amine-terminated starting
dendrimer was 58.4  1.3. The slightly positive zeta potential for the conjugate may be attributed to residual secondary amines on the surface.
¶ Based on high-performance liquid chromatography analysis of percent conjugate peak area versus total peak areas.
# Determined by size-exclusion chromatography coupled with multiple-angle laser light scattering and by matrix-assisted laser desorption
ionization–time-of-flight mass spectrometry analyses.
** Determined by ultraviolet-visible spectroscopy and gel-permeation chromatography–multiple-angle laser light scattering.
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heparin. The peritoneal fluid formed was aspirated gently. The
cells were collected by centrifugation at 300g for 10 minutes
at 4°C. The cell pellet obtained was suspended in 1 ml 10%
HBSS, vortexed for 10–15 seconds to lyse any red blood cells,
and diluted to isotonicity with HBSS. The cells were spun,
counted, and resuspended in a medium containing RPMI 1640
with 20% FBS, 15 mM HEPES, 20 mM L-glutamine, 50 M
2-mercaptoethanol, and 50 g/ml gentamicin, and transferred
to 12-well plates, and the dishes were incubated for 1 hour at
37° in a humidified 5% CO2 incubator to allow the macro-
phages to attach to the dish. The nonadherent cells were
removed and rinsed to remove any residual loosely adherent
cells, and were then incubated with low folate medium over-
night at 37°C in a humidified 5% CO2 incubator. The medium
was changed to fresh medium prior to addition of the conju-
gates.
Flow cytometry studies. The binding of fluorescence-
labeled FA-conjugated dendrimers (G5-FITC-FA) to macro-
phages (RAW 264.7 cells and mouse peritoneal cavity macro-
phages) was evaluated using a Beckman Coulter EPICS-XL
MCL flow cytometer, and the data were analyzed using
Expo32 software (Beckman Coulter). The viable cells were
gated, and the mean fluorescence channel 1 (FL1) fluores-
cence of 10,000 cells was quantified.
Confocal microscopy studies. The RAW 264.7 macro-
phage cell line was visualized using an IX81 inverted micro-
scope (Olympus America) equipped with an FV1000 confocal
unit and a 60/1.4 numerical aperture/0.15-mm oil immersion
objective. For cell imaging, macrophages were plated in glass-
chambered dishes (Nalge Nunc International) and allowed
to adhere for 24 hours at 37°C, followed by washing 2 times
with PBS to remove nonadherent cells. For in vitro staining,
cells were incubated with G5-5T-FA (30 nM) at 37°C for
1 hour before washing 2 times to remove unbound dendrimer
conjugate. A 543-nm HeNe laser was used to excite the
dendrimer–5-TAMRA, and a 405-nm laser diode was used
to excite the DAPI fluorophore. Two-color imaging was per-
formed with 2 spectral detectors (for DAPI, excitation 405 nm,
detector range 455 nm; for the dendrimer–5-TAMRA, ex-
citation 543 nm, detector range 573–648 nm). Images were
processed using FLUOVIEW software (Olympus America).
In vivo studies in a rat arthritis model. The in vivo
studies were conducted at Bolder BioPATH Inc. Female Lewis
rats (Charles River) weighing an average of 150 grams on
day 0 of the study were acclimated to the laboratory conditions
for 7 days. The animals were anesthetized with isoflurane
and given subcutaneous/intradermal injections of 300 l of
Freund’s incomplete adjuvant (Difco) containing 2 mg/ml
bovine type II collagen (Elastin Products) at the base of the tail
and at 2 sites on the back on days 0 and 6. Drug dosing was
initiated on day 0 of the study and continued through day 16.
Immunized rats (n  10 per group) were treated intravenously
3 times per week with 70 mg/kg G5-FA-MTX (G5-FA-MTX-1
or G5-FA-MTX-2; 2 separate batches, equivalent to 5 mg/kg
MTX), 0.2 mg/kg free MTX, or normal saline. Control immu-
nized rats (n  4) were also treated with normal saline using a
similar regimen. The rats were weighed on days 0, 3, 6, and
9–17 of the study, and caliper measurements of the ankles were
obtained every day beginning on day 9. After a final body
weight measurement on day 17, animals were euthanized,
blood was drawn for serum, and tissues were collected. Hind
paws were transected at the level of the medial and lateral
malleolus, weighed, and placed in formalin, with knees, for
microscopy. For histopathologic evaluation, preserved and
decalcified (5% formic acid) ankle and knee joints were cut in
half longitudinally (ankles) or in the frontal plane (knees),
processed through graded alcohols and a clearing agent,
infiltrated and embedded in paraffin, sectioned, stained with
toluidine blue, and analyzed by microscopy.
RESULTS
In vitro studies. We initially determined the
time- and dose-dependent uptake of the fluorescent
conjugate G5-FITC-FA in the RAW 264.7 cells by flow
cytometric analysis. We have used 2 separate lots of
G5-FITC-FA in this study. Both of these lots were
initially tested in KB cells (which express high levels of
FR) and were shown to bind in a dose-dependent and
receptor-saturable manner, and the binding was com-
pletely inhibited by 50-fold excess free FA (data not
shown). An initial time-course analysis using G5-FITC-
FA-1 showed that the conjugate bound to the RAW cells
in a time-dependent manner with maximum binding at
3–4 hours (at 300 nM, G5-FITC-FA-1 showed a mean 
SD FL1 fluorescence of 154  7 at 4 hours). As shown
in Figure 2A, G5-FITC-FA-2 was taken up into the
RAW 264.7 cells in a dose-dependent manner. The
macrophage-activating agent lipopolysaccharide failed
to show any increase in the uptake of the conjugate up to
100 nM of the conjugate, but showed a modest increase
at 300 nM. The control conjugate G5-FITC (300 nM)
failed to show any significant uptake into the
RAW 264.7 cells up to 4 hours. (Incubation with 300 nM
of G5-FITC yielded a net mean  SD FL1 fluorescence
of 5.9  0.7.)
Since the autofluorescence of RAW 264.7 cells at
the emission wavelength of FITC was significant for
confocal analysis, we synthesized conjugates using the
dye 5-TAMRA, whose excitation/emission wavelength
did not result in significant autofluorescence. As shown
in Figure 2B, G5-5T-FA was internalized into the
RAW 264.7 cells, showing localization in the cytosolic
compartment. Consistent with the flow cytometric analy-
sis, the control conjugate G5-5T failed to show any
cellular accumulation. We also tested the conjugate
uptake in the mouse macrophage cell line J774 and
compared it with that of the low–FR expressing mouse
sarcoma cell line MCA-207 (38). In cells treated with
100 nM G5-FITC-FA-1 for 1 hour, flow cytometric
analysis yielded the mean  SD FL1 fluorescence values
of 20.9  8.5 and 4.7  0.8 in excess of those for PBS
controls for the J774 and MCA-207 cells, respectively.
This is consistent with our previous studies showing lack
of cytotoxicity of a G5-FA-MTX drug conjugate in the
MCA-207 cells during a 3-day incubation period (38).
We then isolated mouse peritoneal cavity macro-
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phages and tested the uptake of G5-FITC-FA conjugate
in these cells. As had been observed for the cultured
macrophage cell lines given above, G5-FITC-FA-1
bound to the mouse peritoneal cavity macrophages,
whereas the control conjugate G5-FITC showed only
low binding (Figure 2C). In order to test the FR
specificity of the conjugate, we tested the effect of
preincubation of cells with excess free FA. A 100-fold
molar excess of free FA partially blocked the binding of
G5-FITC-FA in the mouse peritoneal cavity macro-
phages (Figure 2C). Similar partial blocking of the
uptake of G5-FITC-FA by excess free FA was also
observed in the RAW 264.7 cells (data not shown).
In vivo studies in rats with collagen-induced
arthritis. Our previous studies demonstrated that the
dendrimer conjugate G5-FA-MTX acts as a tumoricidal
agent in vivo in the KB xenograft mouse tumor model
with a higher therapeutic index than free MTX (31).
G5-FA-MTX for these studies was synthesized using the
same multistep procedure (28) and then tested in female
Lewis rats using a 17-day type II collagen–induced
arthritis protocol. The rats with collagen-induced arthri-
tis (n  10 for each group) were treated intravenously
3 times a week with vehicle (saline), 2 different batches
of G5-FA-MTX (70 mg/kg for each conjugate, equiva-
lent to 5 mg/kg of MTX), or free MTX (0.2 mg/kg), and
the nonarthritic control rats (n  4) were similarly
treated with vehicle (saline). Efficacy evaluation was
based on ankle caliper measurements, animal body
weight measured from day 9 to day 17, and histopatho-
logic analysis performed on day 17 following euthanasia
of the animals.
As shown in Figure 3, the increased ankle diam-
eter and paw weight measurements caused by arthritis
were decreased in rats treated with the conjugate. Sig-
nificant inhibition of ankle diameter (measured by area
under the curve) was seen in rats treated with G5-FA-
MTX-1 (88% inhibition), G5-FA-MTX-2 (101% inhibi-
tion), or MTX (54% inhibition), as compared to disease
controls. Final paw weights were significantly inhibited
by treatment with G5-FA-MTX-1 (89% inhibition),
G5-FA-MTX-2 (105% inhibition), or MTX (46% inhi-
bition), as compared to disease controls. Moreover, sig-
nificant inhibition of body weight loss due to arthritis
was seen in rats treated with G5-FA-MTX-1 (42%
inhibition), G5-FA-MTX-2 (48% inhibition), or MTX
(38% inhibition), as compared to disease controls
(Figure 3).
Histopathologic evaluations at the end of the
study analyzing ankle and knee inflammation and pan-
nus infiltration, cartilage damage, and bone resorption
clearly indicated protection from arthritis-altered para-
meters by treatment with the conjugates and free MTX.
Figure 2. A, Dose-dependent binding of the fluorescein isothiocyanate
(FITC) conjugate G5-FITC-FA-2 (G5-FI-FA) (at 3 hours of incubation)
to RAW 264.7 cells in the presence (red) or absence (blue) of 1 g/ml
lipopolysaccharide (15 hours of preincubation), analyzed by flow cytom-
etry. Mean  SD fluorescence (in parentheses) under both conditions is
shown. B, Confocal images of RAW 264.7 cells incubated with the
indicated conjugates (orange) and the nuclei stained with DAPI (blue).
Left panels show light microscopy. Right panels show fluorescence
microscopy of the same field. The 2 small boxes are the same areas
containing the 3 cells in the larger box. The larger box is at higher
magnification to demonstrate the uptake of the targeted, fluorescent
dendrimers in the cells. Original magnification  60. C, Binding of
G5-FITC-FA on isolated mouse peritoneal cavity macrophages. Mouse
peritoneal cavity macrophages were incubated with 1 M of G5-FITC
(G5-FI) or G5-FITC-FA-1 (G5-FI-FA) at 37°C for 2 hours in the
presence (blue) or absence (red) of 100-fold excess of free FA, and the
mean  SD fluorescence (in parentheses) was quantified. The mean 
SD fluorescence for the folate receptor–negative MCA-207 cells and the
J774 macrophage cells treated with G5-FITC-FA-1 was 4.7  0.8 and
20.9  8.5 (at 100 nM and 1 hour of incubation), respectively, in excess of
that for phosphate buffered saline (PBS) controls. The data shown are
representative of treatments made in triplicate wells, with similar results
obtained in an independent experiment. See Figure 1 for other
definitions.
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As shown in Figure 4C, normal rats treated with vehicle
showed normal synovium and normal cartilage with no
pannus or bone destruction. Arthritic rats treated with
vehicle had severe synovitis, moderate cartilage damage,
and mild pannus and bone destruction. Arthritic rats
treated with G5-FA-MTX-1 and G5-FA-MTX-2 had
minimal synovitis, no cartilage damage, and no pannus
or bone destruction. Arthritic rats treated with free
MTX had moderate synovitis, minimal cartilage dam-
age, and minimal pannus and bone destruction. Photo-
micrographs with identical trends were observed for the
knee histopathology from the respective groups (not
shown). These parameters were scored on a scale of 0 to
5, with 0, 1, 2, 3, 4, and 5 scored as normal, minimal,
mild, moderate, marked, and severe, respectively. The
effects of the drug conjugates were, however, signifi-
cantly greater than those of free MTX.
We also examined the effects of the conjugates
and the free MTX on organ weights of the animals
(Figure 5). Relative liver and thymus weights for treat-
ment groups did not differ significantly from those for
disease controls. Relative spleen weights were signifi-
cantly increased (above those for normal and disease
controls) following treatment with G5-FA-MTX-1 (18%
increase) or G5-FA-MTX-2 (12% increase), and were
significantly reduced (below those for normal and dis-
ease controls) following treatment with MTX (9% de-
crease).
An independent study was conducted to test the
dose-responsive efficacy of the conjugate versus that of
free MTX (see Figure S1, available on the Arthritis &
Rheumatism Web site at http://onlinelibrary.wiley.com/
journal/10.1002/(ISSN)1529-0131). At the maximum
dose used for the conjugate (225 mg/kg/week) and at the
known maximum tolerated dose for MTX (2 mg/kg/
week), the ankle diameters were reversed to the normal
control values.
DISCUSSION
Several lines of evidence have indicated that
macrophage activation plays a significant role in the
inflammatory pathogenesis of RA (39–42). The concept
of targeting macrophages through FR to treat RA is
supported by the expression of this target in activated
macrophages (39–42), the effectiveness of MTX as a
drug for RA (13,14,42,43), and our previously docu-
mented utility of G5-FA-MTX as a therapeutic agent in
FR-expressing tumor models. We therefore sought to
examine G5-FA-MTX as a DMARD in vivo in a
collagen-induced arthritis model in rats. The results of
our studies provide clear evidence that G5-FA-MTX
acts as a targeted therapeutic for macrophages through
FR effectively suppressing inflammation and arthritis
in the rat model.
Our initial in vitro studies documented that a
Figure 3. Effect of G5-FA-MTX treatment on ankle diameter, paw weight, and body weight of
arthritic rats. A, C, and D, Normal and arthritic rats were treated with free MTX (0.6 mg/kg/week),
G5-FA-MTX-1 or G5-FA-MTX-2 (225 mg/kg/week, equivalent to 15 mg/kg/week MTX), or
vehicle, and the ankle diameter on days 9–17 (A), paw weight (C), and body weight on days 0–17
(D) were measured. B, Area under the curve (AUC) for the data in A was calculated. Values are
the mean  SD.   P  0.05 versus vehicle. See Figure 1 for other definitions.
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FITC-labeled, folate-targeted nanoparticle (G5-FITC-
FA) bound to both FR-expressing macrophage cell
lines and activated peritoneal macrophages in a
receptor-specific manner, and subsequent confocal
microscopic analysis demonstrated the internalization
and cytosolic localization of 5-TAMRA–labeled folate-
targeted nanoparticles in RAW 264.7 cells. The receptor
specificity of this binding was apparent given that the FA
conjugate bound to the FR-expressing macrophages and
cell lines, while control dendrimer conjugates lacking
folate, G5-FITC and G5-5T, failed to bind to these cells.
In contrast to our previous studies in KB cells (28),
however, the binding of G5-FITC-FA could only be
partially inhibited by excess free FA. The reasons for this
incomplete inhibition are not clear, but given that the
Figure 4. A and B, Histopathologic evaluation of the ankles (A) and
knees (B) of arthritic rats treated for 17 days with G5-FA-MTX or free
MTX, obtained from animals in the same experiment as presented in
Figure 3. Values are the mean  SD.   P  0.05 versus vehicle. For
each of the indicated treatment conditions, the bars represent (from
left to right) inflammation, pannus, cartilage damage, bone resorption,
and the average of these 4 parameters. For control nonarthritic rats,
these parameters were all scored as zero (not shown). C, Representa-
tive photomicrographs of stained ankle from normal rats (1) and from
arthritic rats treated with vehicle (2), G5-FA-MTX-1 (3), G5-FA-
MTX-2 (4), and MTX (5). S  synovium. Arrows indicate cartilage
and pannus. Original magnification  16. See Figure 1 for other
definitions.
Figure 5. Effect of G5-FA-MTX on the relative weights of liver (A),
spleen (B), and thymus (C). Rats with collagen-induced arthritis (n 
10) were treated with free MTX, G5-FA-MTX-1 or G5-FA-MTX-2, or
vehicle, and the organ weights were measured on the 17th day of
treatment. Values are the mean  SD percent contributed by each
organ to the body weight of the individual animals.   P  0.05 versus
vehicle. See Figure 1 for definitions.
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control conjugates G5-FITC and G5-5T were not taken
up by macrophages, it is unlikely that a portion of the
uptake of the targeted conjugate was not dependent on
FR. Our findings are similar to those of a previous
study that showed that the uptake of FA-targeted lipo-
somes was completely inhibited by free FA in FR-
expressing IGROV cells but was only 50% inhibited by
free FA in FR-expressing macrophages (44). While it
is tempting to speculate that polyvalent binding of the
FA-targeted nanoparticle to FR-expressing macro-
phages is more avid and therefore more difficult to
compete with than the FR-expressing KB cells, this
finding requires more extensive examination.
Our in vivo studies in the collagen-induced rat
arthritis model clearly documented that administration
of G5-FA-MTX yields significant and beneficial protec-
tion from the inflammatory characteristics of collagen-
induced arthritis (Figure 3). In addition, the time-
dependent increase in the ankle diameter and paw
weight associated with arthritis was almost completely
prevented by administration of the G5-FA-MTX conju-
gate. Moreover, weight loss due to arthritis was pre-
vented in rats treated with the conjugate (Figure 3), and
necropsy histopathology substantiated the prevention of
the inflammatory pathology of the arthritis (Figure 4).
Thus, essentially all arthritis-induced effects, including
infiltration of inflammatory cells, edema of the knee and
ankle, pannus infiltration in cartilage and bone, cartilage
damage, and bone resorption were all significantly pre-
vented by the targeted conjugates (G5-FA-MTX-1 and
G5-FA-MTX-2) (Figure 4). Importantly, as compared to
animals treated with free MTX, the G5-FA-MTX
conjugate–treated animals showed no abnormalities in
their spleen tissue architecture (Figure 5B). This sug-
gests high efficacy for this conjugate in treating joint
inflammation, with the potential for fewer side effects.
Although the inflammatory symptoms were al-
most completely reversed to normal by the conjugates
and MTX, the body weight loss was only partially
reversed by the drugs (Figure 3). The reason for this is
not clear and may be related to handling of the animals.
In this regard, a similar discrepancy has been observed
with Lewis rats treated with MTX and cyclosporin A
(45). In addition, we used a cumulative dose of 0.6
mg/kg/week of free MTX and 15 mg/kg/week of conju-
gate MTX equivalent. Although the maximum tolerated
dose of free MTX in Lewis rats is 2 mg/kg/week (46),
the observed lack of toxicity of the conjugates at 7.5-fold
excess of the maximum tolerated dose predicts the
increased therapeutic index of the targeted drug as
compared to that of the free MTX. A dose-responsive
efficacy study (see Figure S1, available on the Arthritis &
Rheumatism Web site at http://onlinelibrary.wiley.com/
journal/10.1002/(ISSN)1529-0131) showed that the com-
plete reversal of the symptoms of the arthritis required
that free MTX levels be at the maximum tolerated dose
of MTX (2 mg/kg/week). The conjugate showed simi-
lar maximum efficacy at 225 mg/kg/week (equivalent
to 15 mg/kg/week MTX), which is 60% of its maximum
tolerated dose. The apparent increased therapeutic in-
dex of the conjugate versus that of MTX may be
attributed to the fact that the conjugate is primarily
targeted to the macrophages only through FR, whereas
the free MTX is taken up nonspecifically through the
RFC, which is ubiquitous in cells. Single- and multiple-
dose studies of the targeted drug in rats and dogs
revealed no dose-limiting toxicity at the concentrations
used in this study, also suggesting a wide therapeutic
index for this compound (Laveglia, JG, PhD, MPI
Research, Mattawan, MI: personal communication).
Taken together, our studies provide evidence that
the in vivo effect of G5-FA-MTX is a consequence of
targeted drug delivery into macrophages. This parallels
our prior work that showed the specific targeting of
G5-FA-MTX into FR-expressing tumor cells and the
current studies documenting the inability of this conju-
gate to be taken up by FR-negative cells. This was
reinforced by previous studies suggesting the in vitro and
in vivo macrophage uptake of other FA-conjugated
molecules (6–9) and the in vitro documentation of
targeted uptake of G5-FITC-FA into macrophages in
this work (Figure 2).
Together these findings support the utility of
macrophage-targeted therapy for this disease. Despite
this, there are significant differences in activity of G5-
FA-MTX in this arthritis model and what was previously
observed in tumor models. The 2 G5-FA-MTX lots used
in this study were effective in suppressing arthritis, but
the G5-FA-MTX-1 lot was ineffective as a tumoricidal
agent (Baker JR Jr: unpublished observations). The 2
lots of G5-FA-MTX differed primarily in the average
number of FA molecules conjugated to the surface of
the G5 dendrimer (2.5 in the first lot versus 5 in the
second). This suggested that polyvalent interactions
that occur with FR may require less folate for target-
ing, or may be augmented by MTX interactions with this
receptor to yield a sufficiently high binding affinity to
obtain targeting. Further dose-ranging studies will clar-
ify these effects. Unfortunately, the only previous study
using a folate-conjugated G4 PAMAM to treat arthritis
does not clarify these issues, because the drug involved
(indomethacin) was complexed but not covalently linked
to amine-surfaced dendrimers (33). Thus, the observed
increase in indomethacin in the joint may be attributed
2678 THOMAS ET AL
to nonspecific internalization of the positively charged
dendrimer (47). Further confirmation of overall phar-
macokinetics of folate targeting could come from mag-
netic resonance imaging of animals given folate and
gadolinium–conjugated dendrimers (48).
In conclusion, we have demonstrated that FR-
specific targeting of MTX into macrophages via den-
drimers beneficially suppresses inflammatory changes
associated with type II collagen–induced arthritis in rats.
This approach may also serve as a useful targeted
therapeutic strategy for treating other macrophage in-
flammatory diseases such as inflammatory bowel dis-
ease, granulomatous diseases, and atherosclerosis. Al-
ternatively, the current FA-based dendrimer could be
used as a platform to improve the delivery of other
DMARDs such as the TNF blockers, gold salts, chloro-
quine (42,49), or NF-B inhibitors (50).
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